Protara TARA-002 shows 72% CR at 6 months in NMIBC Phase 2; 100% in BCG-unresponsive

Protara Therapeutics, Inc.

72% (13/18) landmark complete response rate at 6 months across BCG exposures; 70% (14/20) at any time.
In BCG-unresponsive pivotal cohort: 100% (4/4) CR at 6 months; 80% (4/5) at any time.
Favorable safety: no Grade 2+ treatment-related AEs; no discontinuations due to AEs; majority Grade 1 and transient.
100% (9/9) maintained CR from 3 to 6 months; 80% (4/5) re-induction salvage rate.
Plans to report initial 12-month evaluable patient data in mid-2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.